US Patent 7427689 ErbB-2 selective small molecule kinase inhibitors
Patent 7427689 was granted and assigned to Georgetown University on September, 2008 by the United States Patent and Trademark Office.
All edits
A novel method for erbB-2 kinase inhibition by compounds identifies through computational modeling and data processing and/or rational and de novo drug design is provided the compounds bind erbB-2 kinase molecules and which can be used as erbB-2 kinase agonists or antagonists. These compounds are useful especially in the treatment of cancer, particularly breast cancer, and can be used alone or in combination with other chemotherapeutic agents, particularly with hercetin, a humanized anti-HER-2 antibody, or with radiation therapy. A specific compound which is exemplified is “compound B17”=methyl-(p-nitrophenyl)-2-propynoate.
US Patent 07427689 ErbB-2 selective small molecule kinase inhibitors US Patent 7427689 ErbB-2 selective small molecule kinase inhibitors
US Patent 07427689 ErbB-2 selective small molecule kinase inhibitors
Find more entities like US Patent 7427689 ErbB-2 selective small molecule kinase inhibitors
